DFPH
Starling Oncology, Inc.
Key Financials
Revenue
$502.7M
↑ 27.8%
Operating Income
$-36083000
↑ 40.0%
Net Income
$-60606000
↑ 6.3%
Total Assets
$164.7M
↓ 4.7%
EPS (Diluted)
$-0.54
↑ 23.9%
Cash & Equivalents
$900000.00
N/A
Total Liabilities
$180.4M
↑ 6.7%
Shareholders' Equity
$-15720000.00
↓ 538.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DFPH |
| Company Name | Starling Oncology, Inc. |
| CIK | 1799191 |
| Sector | Services-Offices & Clinics of Doctors of Medicine |
| Industry | Accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 8011 |
| SIC Description | Services-Offices & Clinics of Doctors of Medicine |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 562-735-3226 |